Resistance mechanisms causing first-line epidermal growth factor receptor-tyrosine kinase inhibitor treatment failure
| Main Authors: | Chai, C.S., Liam, C |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Society for Medical Oncology
2017
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/19181/ http://ir.unimas.my/id/eprint/19181/1/Resistance%20mechanisms%20causing%20first-line%20epidermal%20growth.pdf |
Similar Items
Case Series of Small Cell Lung Cancer Transformation
as Resistance Mechanism to Epidermal Growth Factor
Receptor-Tyrosine Kinase Inhibitor
by: Liam, C, et al.
Published: (2017)
by: Liam, C, et al.
Published: (2017)
Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
by: Chai, C.S., et al.
Published: (2017)
by: Chai, C.S., et al.
Published: (2017)
Small Cell Transformation and T790M Mutation as
Coresistance Mechanisms for First-line Epidermal
Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
by: Chee, Shee Chai
Published: (2017)
by: Chee, Shee Chai
Published: (2017)
Outcome of patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors versus cytotoxic chemotherapy
by: Chai, Chee She
Published: (2015)
by: Chai, Chee She
Published: (2015)
An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)
by: Gutteridge, Eleanor
Published: (2010)
Benzalhydantoin derivative-based inhibitors of eight receptor tyrosine kinases: synthesis, in-vitro, and in-silico study
by: Muhammad Naufal,, et al.
Published: (2025)
by: Muhammad Naufal,, et al.
Published: (2025)
Adaptive therapy to circumvent drug resistance to tyrosine kinase inhibitors in cancer: is it clinically relevant?
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)
by: Hamdi, Amir Imran Faisal, et al.
Published: (2022)
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats
by: Carter, Joanne J., et al.
Published: (2016)
by: Carter, Joanne J., et al.
Published: (2016)
Linifanib – a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator
by: Marlow, Maria, et al.
Published: (2015)
by: Marlow, Maria, et al.
Published: (2015)
Self-assembling tyrosine kinase inhibitors for localised targeted delivery
by: Al-Ameedee, Mohammed
Published: (2017)
by: Al-Ameedee, Mohammed
Published: (2017)
An apoferritin-based drug delivery system for the tyrosine kinase inhibitor gefitinib
by: Kuruppu, Anchala I., et al.
Published: (2015)
by: Kuruppu, Anchala I., et al.
Published: (2015)
EGFR-directed tyrosine kinase inhibitors for non-small cell lung cancer
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)
by: Fatin Nur Elyana Mohd Sidek,, et al.
Published: (2025)
Real-time analysis of the binding of fluorescent VEGF₁₆₅a to VEGFR2 in living cells: Effect of receptor tyrosine kinase inhibitors and fate of internalized agonist-receptor complexes
by: Kilpatrick, Laura E., et al.
Published: (2017)
by: Kilpatrick, Laura E., et al.
Published: (2017)
Determination of gene expression of tyrosine kinase receptors (HER family) in FFPE tissue of colorectal adenocarcinoma
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)
by: Othman @ Jaffar, Rosfayati, et al.
Published: (2015)
Spectroscopic and molecular modeling studies on the interaction of tyrosine kinase inhibitors with human serum albumin / Md. Zahirul Kabir
by: Md. Zahirul , Kabir
Published: (2018)
by: Md. Zahirul , Kabir
Published: (2018)
Effects of receptor tyrosine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2
by: Carter, Joanne J., et al.
Published: (2015)
by: Carter, Joanne J., et al.
Published: (2015)
Characteristics of epidermal growth factor receptor (EGFR)-Mutated Non Small Cell Lung Carcinoma (NSCLC)-patients who developed resistance to first or second generation Egfrtyrosine Kinase Inhibitor (TKI) Therapy through T790M mutation / Vijayan Munusamy
by: Vijayan, Munusamy
Published: (2017)
by: Vijayan, Munusamy
Published: (2017)
Epidermal Growth Factor Receptor Mutation in Newly
Diagnosed Lung Adenocarcinoma
by: Chee, Shee Chai, et al.
Published: (2017)
by: Chee, Shee Chai, et al.
Published: (2017)
Survival rate and prognostic factors of survival among chronic myeloid leukaemia adults after initiation of tyrosine kinase inhibitor therapy in Hospital Ampang, Selangor
by: Ali, Zakiah Bakar
Published: (2024)
by: Ali, Zakiah Bakar
Published: (2024)
Targeting the hypoxic expression of epidermal growth factor receptor
by: Alamoudi, Abdulmohsin
Published: (2021)
by: Alamoudi, Abdulmohsin
Published: (2021)
The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets
by: Canobbio, I., et al.
Published: (2015)
by: Canobbio, I., et al.
Published: (2015)
The proline-rich tyrosine kinase Pyk2 regulates platelet integrin aIIbß3 outside-in signaling
by: Cipolla, L., et al.
Published: (2013)
by: Cipolla, L., et al.
Published: (2013)
Translational control of epidermal growth factor receptor in neurodegenerative diseases
by: Smalley, Daniel. S.
Published: (2017)
by: Smalley, Daniel. S.
Published: (2017)
Role of Focal Adhesion Tyrosine Kinases in GPVI-Dependent Platelet Activation and Reactive Oxygen Species Formation
by: Carrim, N., et al.
Published: (2014)
by: Carrim, N., et al.
Published: (2014)
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
by: Yu, Yu, et al.
Published: (2015)
by: Yu, Yu, et al.
Published: (2015)
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2010)
by: Miles, D., et al.
Published: (2010)
A phase 2 trial of decreasing tyrosine kinase inhibitor dose in chronic myeloid leukaemia patients with stable major molecular response: data from the British DESTINY study
by: Clark, Richard E., et al.
Published: (2017)
by: Clark, Richard E., et al.
Published: (2017)
A randomized control trial comparing peginterferon-α-2a versus observation after stopping tyrosine kinase inhibitor in chronic myeloid leukemia with deep molecular response for at least two years
by: Kuan, Jew-Win, et al.
Published: (2016)
by: Kuan, Jew-Win, et al.
Published: (2016)
Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2
by: Canobbio, I., et al.
Published: (2013)
by: Canobbio, I., et al.
Published: (2013)
Src family tyrosine kinase Lyn mediates VWF GPIb-IX induced platelet activation via the cGMP signaling pathway
by: Yin, H., et al.
Published: (2008)
by: Yin, H., et al.
Published: (2008)
A prospective study on epidermal growth factor receptor mutations in non-small cell lung cancer in Malaysian patients
by: Liam, C K, et al.
Published: (2012)
by: Liam, C K, et al.
Published: (2012)
Identification of a novel invariant splice site mutation of Bruton's tyrosine kinase (BTK) gene in a Malaysian family with X-linked agammaglobulinemia / Chear Chai Teng
by: Chear, Chai Teng
Published: (2014)
by: Chear, Chai Teng
Published: (2014)
Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis
by: Koh, Rhun Yian, et al.
Published: (2015)
by: Koh, Rhun Yian, et al.
Published: (2015)
Editorial: Platelet hem-Immunoreceptor Tyrosine-Based Activation Motif Receptors: At Lease One Required
by: Berndt, Michael, et al.
Published: (2013)
by: Berndt, Michael, et al.
Published: (2013)
Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma
by: Abbhi, V., et al.
Published: (2017)
by: Abbhi, V., et al.
Published: (2017)
The tyrosine kinase Pyk2 mediates the cross-talk between platelet integrins alpha 2 beta 1 and alpha IIb beta 3
by: Guidetti, G., et al.
Published: (2011)
by: Guidetti, G., et al.
Published: (2011)
The tyrosine kinase PYK2 mediates the cross-talk between platelet integrins alpha 2 beta 1 and alpha iib beta 3
by: Guidetti, G., et al.
Published: (2011)
by: Guidetti, G., et al.
Published: (2011)
Biological significance of human epidermal growth factor receptor 2 (HER2) in breast cancer: effect of oestrogen receptor
by: Ahmad, Dena Akram Jerjees
Published: (2016)
by: Ahmad, Dena Akram Jerjees
Published: (2016)
Flavokawain B Induced cytotoxicity in Two Breast Cancer Cell Lines, MCF-7 and MDA-MB231 and Inhibited the Metastatic Potential of MDA-MB231 via the Regulation of Several Tyrosine Kinases In vitro
by: Nadiah, Abu, et al.
Published: (2016)
by: Nadiah, Abu, et al.
Published: (2016)
Flavokawain B induced cytotoxicity in two breast cancer cell lines, MCF-7 and MDA-MB231 and inhibited the metastatic potential of MDA-MB231 via the regulation of several tyrosine kinases in vitro
by: Abu, Nadiah, et al.
Published: (2016)
by: Abu, Nadiah, et al.
Published: (2016)
Similar Items
-
Case Series of Small Cell Lung Cancer Transformation
as Resistance Mechanism to Epidermal Growth Factor
Receptor-Tyrosine Kinase Inhibitor
by: Liam, C, et al.
Published: (2017) -
Case series of small cell lung cancer transformation post tyrosine kinase inhibitor failure
by: Chai, C.S., et al.
Published: (2017) -
Small Cell Transformation and T790M Mutation as
Coresistance Mechanisms for First-line Epidermal
Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy Failure
by: Chee, Shee Chai
Published: (2017) -
Outcome of patients with advanced lung adenocarcinoma treated with first-line epidermal growth factor receptor tyrosine kinase inhibitors versus cytotoxic chemotherapy
by: Chai, Chee She
Published: (2015) -
An investigation into the effects of the epidermal growth factor receptor tyrosine kinase inhibitor "Gefitinib" on human breast cancer
by: Gutteridge, Eleanor
Published: (2010)